LYVE-1 has been identified as a major receptor for HA (extracellular matrix glycosaminoglycan hyaluronan) on the lymph vessel wall. The deduced amino acid sequence of LYVE-1 predicts a 322-residue type I integral membrane polypeptide 41% similar to the CD44 HA receptor with a 212-residue extracellular domain containing a single Link module the prototypic HA binding domain of the Link protein superfamily. Like CD44, the LYVE-1 molecule binds both soluble and immobilized HA. However, unlike CD44, the LYVE-1 molecule colocalizes with HA on the luminal face of the lymph vessel wall and is completely absent from blood vessels. Hence, LYVE-1 is the first lymph-specific HA receptor to be characterized and is a uniquely powerful marker for lymph vessels themselves.
应用类型
WB, IHC
免疫原
该Anti-Human Lyve-1的详细信息查看ReliaTech提供的产品说明书。
来源宿主
该Anti-Human Lyve-1的详细信息查看ReliaTech提供的产品说明书。
反应性
该Anti-Human Lyve-1的详细信息查看ReliaTech提供的产品说明书。
保存建议
该Anti-Human Lyve-1的详细信息查看ReliaTech提供的产品说明书。溶解建议：Centrifuge vial prior to opening. Reconstitute the antibody with 500 µl sterile PBS and the final concentration is 200 µg/ml.
